Acquisition Pending
Zymeworks acquisition of Theravance Biopharma
US$929m consideration
Announced 29 Jun 2026 · NASDAQ: TBPH · US$17.00 cash and scrip per share
Advisers
Theravance Biopharma
Target
- Legal adviser
- Fairness opinion
Zymeworks
Acquirer
- Financial adviser
- Legal adviser
- Tax adviser
Other advisers
- Financial adviser
- Target
- Theravance Biopharma
- Acquirer
- Zymeworks
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Pharma
- Tags
- Pharma, Biotech
In the league tables
Similar deals
- Eli Lilly and Company acquisition of Ventyx Biosciences Jan 2026 · US$1.2bn · Biotech
- Otsuka acquisition of Transcend Therapeutics Mar 2026 · US$700m · Biotech
- Teva Pharmaceuticals acquisition of Emalex Biosciences Apr 2026 · US$700m · Pharma
- UCB acquisition of Neurona Therapeutics Apr 2026 · US$650m · Biotech
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
Sources
- Jun 2026 Kirkland Advises Zymeworks on Acquisition of Theravance kirkland.com
- 29 Jun 2026 Press release (EX-99.1, exhibit), THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE sec.gov
- 29 Jun 2026 Press release (EX-99.1, exhibit), Zymeworks to Acquire Theravance Biopharma, Inc. sec.gov
- 29 Jun 2026 Press release (PR Newswire), THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT prnewswire.com
- 21 Aug 2026 Definitive merger proxy statement (DEFM14A), Theravance Biopharma, Inc. sec.gov
- 23 Sep 2026 Lazard: CANADA, CAYMAN ISLANDS Zymeworks to Acquire Theravance Biopharma lazard.com




